CORTEXA
← Browse
openalexFrontiers in Oncology2026-07-24Cited by 0

Phosphorylation of tumour suppressor Amotl2 by IKBKE kinase promotes YAP1 signalling, enhancing glioblastoma growth

Gaochao Guo, Yan Sun, Rujun Hong, Yalin Lu, Xingjie Chen, Liming Zhao, Chaoyue Li, Yang Liu, Qiang Huang

Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), a member of the serine/threonine kinase family, is an important oncogene in glioblastoma. IKBKE is involved in the progression of multiple tumours in glioblastoma (GBM), including tumour invasion, migration, and proliferation. Here, we report an IKBKE–angiomotin-like protein 2 (Amotl2)–yes-associated protein 1 (YAP1) axis in which IKBKE inhibits the protein expression of Amotl2, while Amotl2 regulates the nuclear transport of the YAP1 protein, which has been implicated in brain tumour development and progression. Data analysis of multiple IKBKE mRNA databases of glioma and immunohistochemical analysis of a tissue chip indicated that higher IKBKE expression was associated with higher malignancy and shorter survival in glioma patients. IKBKE downregulation significantly inhibited GBM cell proliferation and restrained tumour growth in a GBM mouse model. Moreover, IKBKE phosphorylates Amotl2, promoting Amotl2 ubiquitination and degradation, leading to YAP1 entry into the nucleus and the activation of downstream genes. In summary, our results are the first to show that IKBKE phosphorylates Amotl2 and that GBM cell proliferation is regulated by the IKBKE↑–Amotl2↓–YAP1↑ axis.

View free PDFSource page

Related papers

openalexFrontiers in Oncology2026-07-24

Case Report: Long-term survival in extensive-stage small cell lung cancer treated with adebrelimab-based combination therapy

Xia Y, Yuxian Yang, Wanzhong Huang, Yongshun Chen

The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a deta…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells

R K Watanabe, Mami Chosei, Haruna Arai, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika

Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive treatment-associated lineage state emerging with potent androgen receptor (AR) pathway inhibition. Although treatment-emergent NEPC is increasingly recognized, the transcriptional consequences of sustained AR sup…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Construction and validation of a machine learning model for predicting anastomotic leak following radical esophagectomy for esophageal cancer

Yueying Yang, Kayishaer Ainiwaer, Yunfei Gao, An Li, Abulajiang Kamili, Dongbo Luo

Background Early identification of patients at high risk of anastomotic leak (AL) following esophagectomy is essential for improving surgical outcomes. However, reliable preoperative risk stratification remains challenging. This study aimed to predict AL risk in the esophageal ca…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Spontaneous rupture of a clinically recurrent intracranial dermoid cyst: a case report and narrative review

Hongyuan Liu, Hui Zeng, Bufan Yang, Yuzhu Ji, Zongping Li, Liangxue Zhou

Objective To describe the clinical, pathological, and therapeutic features of spontaneous rupture of a recurrent intracranial dermoid cyst (IDC), and to summarize relevant dermoid-specific literature. Methods We report a 38-year-old woman with a clinical history of resection of a…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies

Ashley R Tetens, Jordyn Craig-Schwartz, Tyler Findlay, Michael A. Koldobskiy

The advent of cancer immunotherapy has led to dramatically improved outcomes in several immunogenic adult cancers. Similar successes have been seen in some pediatric cancers, but only in specific settings. A particular challenge has been the application of immunotherapy approache…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Liver resection is associated with better survival than TACE for hepatocellular carcinoma modestly beyond Milan criteria: a multicenter propensity-matched analysis

Xiaoyan Fan, Guobin Sun, Yong Meng, Liu Xm, Li Zhang, Yan Peng, et al.

Background and aim Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) within extended transplant criteria, but it is available to only a minority of patients. The optimal alternative treatment strategy for patients with HCC beyond th…

View free PDFSource page